Pharmaceutical R&D company Sellas Life Sciences surged 220% at market open
According to MSX.COM data, pharmaceutical R&D company Sellas Life Sciences surged 220% at market open. The company said on Tuesday that its experimental vaccine targeting a blood cancer achieved positive results in a late-stage clinical trial, helping patients significantly extend their survival time.
